Trevi Therapeutics (TRVI) Earnings Transcript

Trevi ended 2025 with $188M in cash, cash equivalents and marketable securities (runway into 2028) and secured FDA alignment to launch two parallel global Phase III trials for IPF-related chronic cough: a 52-week study (primary efficacy at 24 weeks, ~300 patients) starting in Q2 2026 and a 12-week study (~130 patients) expected in H2 2026. Management also plans an adaptive Phase IIb → Phase III pathway for non-IPF ILD (Type C meeting planned in Q3 2026) and a RCC Phase IIb parallel-arm dose-ranging trial (3 doses + placebo) with an interim sample-size reestimation later in 2026. Key caveat: the cash runway covers the 12‑week Phase III readout and other Phase II/IIb milestones but does not fund the 24‑week IPF readout because the FDA requires a 52‑week controlled safety period, creating potential near-term funding timing risk.

Analysis

Trevi’s program structure creates a financing cliff that will likely surface before the pivotal safety database is unblinded — that mismatch is the single largest value driver and the most actionable near-term risk. Expect capital markets activity (secondary offering, structured equity, or a partnering milestone deal) within the next 6–12 months; pricing and deal structure there will re-set implied dilution and should be the primary determinant of near-term downside.

Regulatory signals from the division handling fibrotic lung disease have raised the marginal cost of entry for cough assets: longer controlled exposure and label‑enabling DDI work increase total program costs materially, shifting comparative advantage to better‑funded teams or companies willing to license. That raises the odds that a well‑timed external partner or M&A premia could emerge if Trevi posts favorable interim signals — conversely, failure to secure exclusivity (or a narrow label) would compress NPV by a material multiple.

Clinically, placebo variability and background antifibrotic use are the two wildcards that dictate required sample size and commercial label breadth. The built‑in sample‑size re‑estimation reduces binary risk from an underpowered initial assumption, but it does not eliminate the dilution or timeline consequences of a wider than expected placebo response or emergent DDI findings with newly approved antifibrotics.

Commercially, the company’s strategy to leverage overlapping specialist networks is high‑leverage: if regulatory and reimbursement hurdles are modest, adoption curves in specialty centers could be steep and front‑loaded, compressing payback periods. That same concentration of prescribers also makes the asset attractive to an acquirer that can supply launch infrastructure and payer access, implying M&A is a realistic mid‑to‑long‑term exit path if clinical readouts land positively.

Key Decisions for Investors

• Long TRVI via a defined‑risk call spread (size 1–2% NAV): buy Jan‑2028 LEAP calls and sell a higher‑strike Jan‑2028 call to finance ~50–75% of the premium. Rationale: captures full pack of pivotal catalysts (interim re‑estimation, 12‑week readout, potential partnership interest) while capping premium loss. Target reward: 3x+ if catalysts succeed; max loss = premium paid.
• Buy TRVI equity (size 1–3% NAV) and hedge idiosyncratic trial risk by shorting a broad small‑cap biotech ETF (size = 0.5–1% NAV, e.g., inverse exposure 1:1 notional). Rationale: isolates Trevi‑specific upside from sector beta; trim equity position into positive interim readouts or after May investor/ATS events. Downside: single‑asset dilution risk; use stop at 30% drawdown.
• Event credit / pre‑fundraise play: if a secondary appears, consider participating via a standby or small make‑whole allocation only after price discovery; otherwise buy protective Jan‑2027 puts (size 0.5% NAV) to limit downside into the anticipated financing window. Rationale: protects against the most likely equity‑dilution shock between now and the larger safety database completion.
• M&A conditional leg: maintain a watchlist (notional stake ≤1% NAV) sized to be increased on a favorable interim readout or demonstrated DDI absence; peer acquirers (specialty pharm with pulmonary franchises) will likely pay a 30–60% premium in an expedited deal. Rationale: acquisition is a high‑probability path to monetize positive phase‑III signals for mid‑stage chronic‑cough assets.